Modexa

Symptoms of seasonal allergic or perennial rhinitis in adults, adolescents, & childn 2-11 yr. Prophylactic treatment in patients w/ history of moderate to severe symptoms of seasonal allergic rhinitis. Nasal polyps & associated symptoms including congestion & loss of smell in adults ≥18 yr. Symptoms associated w/ acute rhinosinusitis in patients ≥12 yr w/o signs or symptoms of severe bacterial infection. Adjunctive treatment to antibiotics for acute episodes of sinusitis in adults & adolescents ≥12 yr.

Seasonal allergic or perennial rhinitis Adult (including elderly) & adolescent 2 sprays in each nostril once daily. Maintenance: 1 spray in each nostril. Max: 4 sprays in each nostril once daily if symptoms are inadequately controlled. Reduce dose following control of symptoms. Childn 2-11 yr 1 spray in each nostril once daily. Nasal polyposis Adult (including elderly) & adolescent ≥18 yr 2 sprays in each nostril bid. Reduce dose to 2 sprays in each nostril once daily once symptoms are adequately controlled. Acute rhinosinusitis 2 sprays in each nostril bid. Adjunctive treatment of acute episodes of sinusitis Adult (including elderly) & adolescent ≥12 yr 2 sprays in each nostril bid, may be increased to 4 sprays in each nostril bid if symptoms are inadequately controlled.

Hypersensitivity.

Rare reports of immediate hypersensitivity reactions. Signs or symptoms of severe bacterial infection (eg, fever, persistent severe unilateral facial/tooth pain, orbital or periorbital facial swelling, or worsening of symptoms after an initial improvement). Caution in patients w/ active or quiescent tuberculous infection of resp tract, or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex. Examine patients periodically for possible changes in nasal mucosa, including development of nasal ulcerations if used over several mth or longer. Discontinue or require appropriate treatment if localized fungal infection of nose or pharynx develops. Risk of infections (eg, chickenpox, measles) in patients who are potentially immunosuppressed. Risk of visual disturbances. Do not use in patients w/ recent nasal surgery or trauma until healing has occurred. Very rare reports of nasal septum perforation or increased IOP; anaphylaxis & angioedema; disturbance of taste & smell. Pregnancy & lactation. Safety & efficacy for treatment of symptoms of rhinosinusitis in childn <12 yr, & for treatment of nasal polyposis in childn & adolescents <18 yr have not been studied.

Headache, epistaxis (eg, frank bleeding, blood-tinged mucus, & blood flecks), pharyngitis, nasal burning, nasal irritation, & nasal ulceration. Blurred vision.

Increased plasma conc & potentially increased risk for systemic corticosteroid adverse effects w/ strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing products).

Nasal Decongestants & Other Nasal Preparations

R01AD09 - mometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.

Rx